fbpx

Location:  Jackson, TN; Orlando, FL

Indication:  Atopic Dermatitis and Healthy Controls

Sponsor: Precision Biospecimen Solutions, Inc.

PI: Dafnis Carranza, MD; Christopher Chappel, MD

Intervention/Treatment: Biospecimen collection

Ages: 18+

Criteria:

  • Subjects with a documented diagnosis of Atopic Dermatitis
    • Diagnosis must be within one year
  • Healthy subjects without a diagnosis of Atopic Dermatitis or generalized dermatology conditions

Compensation: You may be compensated for your time and participation

Location: Orlando, FL

Indication: Urticaria

Sponsor: Teva Pharmaceuticals USA

PI: Christopher Chappel, MD

Intervention/Treatment: TEV-45779 and XOLAIR®️️️

Age: 18-75

Criteria:
• Has diagnosis of CIU refractory to H1 antihistamines for ≥3 months
• Does NOT have chronic urticaria with clearly defined underlying etiology
• Does NOT have other skin disease associated with itch

Compensation: You may be compensated for your time and participation

About: The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.

Start typing and press Enter to search